The fixed-dose ledipasvir-sofosbuvir combination offers an effective and well-tolerated pill for the treatment of chronic hepatitis C infection. Only a few analytical works were carried out to estimate the Ledipasvir and Sofosbuvir drug combination in the various dosage forms. This work aimed to simplify the estimation process using RP-HPLC methodology. The method was developed on a reversed phase Agilent C18 (4.6 x 150 mm, 5 µm) column. The isocratic elution process was performed using a mobile phase ratio of Methanol (70% v/v): Water (30 % v/v) with 0.6 ml/min flow rate. Elute was scanned using the PDA detector at the wavelength of 235 nm. The results of the elution process showed that the Ledipasvir and Sofosbuvir elute the peak at a concentration of 9 μg/ml and 40 μg/ml with retention times of 7.745 min and 2.345 min respectively. The percentage purity of Ledipasvir and Sofosbuvir was found to be 99.40 % w/v and 98.20 % w/v. The proposed method was found to be a high degree of precision and reproducibility. The percentage recovery was found to be 99.92 % for Ledipasvir and 99.82 % for Sofosbuvir. The LOD and LOQ were measured, and the results were within limits. The developed validation method can be applied for degradation evaluation of Ledipasvir and Sofosbuvir for the various dosage forms.
INTRODUCTION
Ledipasvir is the first approved NS5A inhibitor agent for HCV genotype 1 treatment (Waheed Yasir., 2015) (Fig.1) . The Ledipasvir possessed multiple hetero rings such as benzimidazole, imidazole, pyrrole, etc. It also contains the carbonyl amino, fluoro and carbamate groups. The pharmacokinetic parameter of the drug showed >99.8% protein binding, the plasma half-life of 47 hrs and the renal clearance of 1% (Devilal J et al., 2016) . Sofosbuvir, secondhand agent for the combination therapy to treat chronic Hepatitis C with Ledipasvir (Keating GM., 2014) (Fig.2) . It contains a furan ring in the center with the surrounding of various fragments of pyrimidine, phenoxy, phosphoryl amino and methyl ester group (Jahnavi Bandla et al., 2017) . Sofosbuvir found 61-65 % of protein binding, 0.4 hr of plasma half-life and 80% renal clearance (Guguloth R et al., 2016) .
FDA approved the fixed dose combination of ledipasvir-sofosbuvir for the sustained virological response (Akshay P. Rote et al., 2017; Bakht Zaman et al., 2016) . The primary data revealed that the combination offers effective treatment of hepatitis C infection, and it is well tolerated in oral dosage forms. It is imperative to have safety and efficacy in drug therapy; pharmacists must take into consideration the stability of drugs and their therapeutic values. The stability of the drug formulations can be assessed by using stability indicating methods (Battula Sreenivasa et al., 2017) . A well-designed stress study is important to help develop and demonstrate the specificity of stability indicating methods (Nebsen M et al., 2016) . They are also useful in checking rapid and accurate drug quality during stability testing (Ewing GW et al., 1997) . There is no cost-effective analytical method reported (consuming less amount of mobile phase) for simultaneous analysis of Ledipasvir and Sofosbuvir, previous to our work (Hassouna MEM et al., 2017; Kranthi Kiran K et al., 2017; Nagaraju T et al 2017; Uppalapati. Jyothi et al., 2017; Yogendrachari K et al 2016; Madhavi S et al., 2017) . The present work is aimed at to develop a novel, rapid, affordable, reliable, cost-effective, selective, sensitive, precise, accurate, reproducible, and specific analysis of combination (Ledipasvir and Sofosbuvir) in various dosage forms using stability indicating RP-HPLC method.
MATERIALS AND METHODS
Authentic drug samples of Ledipasvir and Sofosbuvir were obtained from Pharma Train Lab, Hyderabad. The commercial samples of the tablets Hepcinat-LP containing Ledipasvir -90 mg and Sofosbuvir-400 mg were provided by Natco Pharmaceuticals Pvt.Ltd, Hyderabad. All the solvents were HPLC grade and purchased from the Sigma Aldrich.
Chromatographic process and conditions
Waters e2695 Separation Module HPLC autosampler system and a UV-visible detector were used for the chromatographic separation.
The chromatographic column utilized in the study was Agilent C18 (4.6 × 150 mm, 5µm). Different mobile phases were tried, and the one containing Methanol: Water in the ratio of 70: 30 % v/v was appropriate. The mobile phase was used as a diluent. The flow rate selected was 0.6 ml/min. The overlay spectrum of Ledipasvir and Sofosbuvir was obtained, and the isobestic point of Ledipasvir and Sofosbuvir showed absorbance's maxima at 235 nm (Rai SY et al., 2017) (Fig.3) . Accurately weighed pure drugs of Ledipasvir 90 mg and 400 mg of Sofosbuvir for working standard preparation and 20 ml of diluent (methanol: water) was added in 100 mL standard flask. Further, it was sonicated and made up to the volume. The final concentration of 9.0 µg/ml Ledipasvir and 40.0 µg/ml Sofosbuvir was prepared from the stock solution. Similarly, the marketed sample Hepcinat-LP tablets with the label claim of 90 mg of Ledipasvir and 400mg Sofosbuvir was powdered and placed into a 100 ml volumetric flask. The sample solution is prepared as a similar standard concentration of 9.0 µg/ml Ledipasvir and 40.0 µg/ml Sofosbuvir, respectively.
Assay
Initially, 10μl of standard solution and simultaneously sample solution was injected and the peak areas of the drugs in standard and sample compared. Ledipasvir and Sofosbuvir show the percentage purity values of 99.40 % w/v and 98.20 % w/v respectively (Table 1 & 2) .
RESULTS AND DISCUSSION

Specificity
There are no elutions of interfering peak takes place, which shows that the peak of the analyte was pure, and excipients in the combination do not interfere with the analyte (Fig.4) . Therefore, the method is specific and selective for the estimation of Ledipasvir and Sofosbuvir in the combination. 
Linearity and Range
Linearity and range measured for the working standard by the various diluted concentration of 7.2, 8.1, 9.0, 9.9 and 10.8 μg/ml for Ledipasvir and 32,36,40,44 and 48μg/ml for Sofosbuvir respectively. From the results of linearity studies, the specified range was determined for Ledipasvir & Sofosbuvir given as 7.2 -10.8 μg/ml and 32 μg/ml -48 μg/ml (Table 3 ). The calibration curves are shown in (Fig.5 & 6) . The Correlation Coefficient for Ledipasvir & Sofosbuvir was found to be within the acceptance criteria of 0.999. Table 4 & 5. The chromatograms are shown in (Fig.7) .
Method Precision
In the same way, method precision was determined by six repeat injections of a mixed combination of the sample solution of 9.0 µg/ml Ledipasvir and 40.0 µg/ml Sofosbuvir. The Table- (Table-6 & 7) . The chromatograms are shown in (Fig.8) .
Thus the proposed method was found to be a high degree of precision and reproducibility.
Inter-day Precision: To check the inter-day variations of the method, the same concentration of Ledipasvir and Sofosbuvir were subjected to the proposed HPLC method of analysis on different days, and the results obtained were noted. The R.S.D % of peak area was 0.4186 and retention time was 1.344 for Ledipasvir. The R.S.D % of peak area was 0.442 and retention time was 0.117 for Sofosbuvir. Statistical evaluation revealed that parameters found were within the acceptance range of R.S. D<2% (Table 8) . Thus, the proposed method was found to have a high degree of precision and reproducibility.
System Suitability: To elucidate the system suitability, six repeated injections of a mixed standard The parameters including resolution, tailing factor, no. of theoretical plates were mainly used to assess system suitability. Table 9 and Fig-9 showed tailing factor for Ledipasvir & Sofosbuvir was found to be 1.74 and 1.80, respectively. The Theoretical plates per unit for Ledipasvir & Sofosbuvir was found to be 2741 and 2529.7 respectively. The resolution value of Ledipasvir & Sofosbuvir was found to be 6.42. The chromatograms are shown in (Fig.9) .
Accuracy
The targeted concentration of 7.2 µg/ml, 9.0 µg/ml and 10.8 µg/ml of Ledipasvir & 32 µg/ml, 40 µg/ml and 48 µg/ml of Sofosbuvir working standards were spiked with Placebo and each injected thrice It was performed changing the HPLC pump flow rate variations ± 0.2 ml/min and organic composition of the mobile phase ±5%. U.S.P Plate count and U.S.P tailing were found to be 2890.0 and 1.72 for 0.4 ml/min flow rate for Ledipasvir. U.S.P Plate count and U.S.P tailing were found to be 2563.1 and 1.71 for 0.8 ml/min flow rate for Ledipasvir. U.S.P Plate count and U.S.P tailing were found to be 2313.2 and 1.82 for 0.4 ml/min flow rate for Sofosbuvir. U.S.P Plate count and U.S.P tailing were found to be 2684 and 1.74 for 0.8 ml/min flow rate for Sofosbuvir. U.S.P Plate count and U.S.P tailing were found to be 2867 and 1.70 for 5% less organic composition in mobile phase for Ledipasvir. U.S.P Plate count and U.S.P tailing were found to be 2654.4 and 1.61 for 5% more organic composition in mobile phase for Ledipasvir. U.S.P Plate count and U.S.P tailing were found to be 2356 and 1.81 for 5% less organic composition in mobile phase for Sofosbuvir. U.S.P Plate count and U.S.P tailing were found to be 2231.4 and 1.82 for 5% more organic composition in mobile phase for Sofosbuvir. No changes were observed in chromatograms when changing the flow rate and the concentration of the mobile phase. The chromatograms are shown in (Fig.10 -13) , and results are reported in Table 12 .
Ruggedness
Mixed standard solution of Ledipasvir & Sofosbuvir was prepared by adding diluent as per test method separately by Analyst -I and Analyst -II. 10 µl of these solutions were injected for six times and the % RSD for the Peak area of six replicate injections were calculated for Analyst -I and Analyst -II. The % R.S.D of Peak area for Analyst I and Analyst II was found to be 0.43 and 0.27 for Ledipasvir. The % R.S.D of Peak area for Analyst I and Analyst II was found to be 0.39 and 0.54 for Sofosbuvir. The % R.S.D of peak area was present within the acceptance criteria of 2%. The low values of the % RSD, indicate the ruggedness of the proposed methods (Table 13) .
Estimation of LOD and LOQ
LOD = 3.3 X σ LOQ = 10 X σ
The LOD of Ledipasvir and Sofosbuvir were 0.208 µg/ml and 0.341 µg/ml. The obtained LOD values were very less when equated to the reported method. As per the analytical point of view, the method detects the very least quantity. So when compared to the reported methods, the developed method is most suitable to detected less quantity. The LOQ of Ledipasvir and Sofosbuvir were 0.631 µg/ml and 1.034 µg/ml, respectively. The obtained LOQ values were very less when compared to reported methods. As per the analytical point of view, the method detected the very least quantity. So when compared to the reported methods, the developed method is most suitable to detect less quantity. The results are reported in Table 14 .
